Emyria (EMD) Q4 2025 TU earnings summary

Executive summary

• Secured a multi-year funding agreement with Medibank to fund eligible PTSD patients in the Empax program, marking a national first for psychotherapy-led reimbursement.

• Opened a second Empax Centre at Perth Clinic, expanding capacity for PTSD and treatment-resistant depression programs.

• Six-month follow-up data from the first Empax PTSD cohort showed 63% no longer met PTSD criteria and a 121.5% improvement in quality-of-life scores.

• Raised $4M through a placement to accelerate growth and expand patient access, with strong institutional and director support.

• Chief Scientific Officer presented at Psychedelic Science 2025, highlighting the Medibank agreement and real-world data model.

Financial highlights

• Net operating cash outflow for the quarter was $954,000; customer receipts totaled $354,000.

• Cash at quarter end was $3.57 million, with an additional $1.1 million expected in August pending shareholder approval.

• Placement raised $4M before costs, including $197,000 director participation.

• Estimated 3.74 quarters of funding available based on current cash burn.

Outlook and guidance

• Plans to expand clinic footprint nationally and extend reimbursed programs to cover more mental health indications.

• Focus on deepening engagement with additional insurers and public payers.

• Continued investment in real-world data infrastructure to enhance personalized care and create licensable IP.